On August 10, 2026, Inventisbio announced the signing of a collaboration agreement with MSD R&D (China) to jointly advance the clinical co-development of anti-tumor drugs.
Inventisbio has solid scientific foundations and innovation capabilities in anti-tumor drug research and development. The company is dedicated to discovering and developing innovative drugs with independent intellectual property rights that are safe and effective, addressing the unmet clinical needs of patients in China and globally. This collaboration will combine the strengths of both parties to accelerate the clinical development of innovative candidate drugs, providing patients with more breakthrough treatment options.
JunHe was entrusted by Inventisbio to review, revise and negotiate the agreement for this project. JunHe earned the trust and recognition of the client with its consistently efficient, rigorous work style and meticulous, dedicated service attitude.
The partners responsible for this project were LI, Chenliang, ZHAO, Hao (Gerry) and WANG, Juewei (Jewel).
